Removab is indicated for the intraperitoneal treatment of malignant ascites in adults with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible.
I am a medical doctor (MD, PhD.) on oncology, but I have never used Removab, anti-CD3 and anti-EpCAM. The spheroids in the ascites of the malignant ovarian cancer patients are sensitive to Removab, which implies cancer stem-like cells in the spheroids tend to depend on EpCAM expression-induced Wnt/beta-catenin signaling pathway. Give that EpCAM contributes to the cell adhesion, however, I wonder why non-adhesion tumor cells highly express EpCAM. Does beta-catenin accumulate in the nucleus of the tumor cells composed of spheroids???